Cambridge Advisors Inc. continued to hold its position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,165 shares of the medical instruments supplier’s stock at the end of the second quarter. Cambridge Advisors Inc.’s holdings in Becton, Dickinson and were worth $618,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Crestwood Advisors Group LLC acquired a new position in Becton, Dickinson and during the first quarter worth about $101,000. North Star Investment Management Corp. boosted its position in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust boosted its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares in the last quarter. Finally, Financial Architects Inc boosted its position in Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares in the last quarter. 75.57% of the stock is owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 0.58% during mid-day trading on Monday, hitting $201.53. The stock had a trading volume of 499,611 shares. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The stock’s 50-day moving average is $198.90 and its 200-day moving average is $187.70. The firm has a market capitalization of $45.86 billion, a PE ratio of 58.36 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same period last year, the firm posted $2.35 earnings per share. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.46%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/becton-dickinson-and-company-nysebdx-stake-maintained-by-cambridge-advisors-inc/1486901.html.

A number of research analysts recently issued reports on the company. Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $186.00 to $200.00 in a report on Monday, April 24th. Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday. Finally, Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and currently has an average rating of “Buy” and an average target price of $195.79.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares in the company, valued at $2,538,890.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The disclosure for this sale can be found here. Insiders have sold 44,019 shares of company stock valued at $8,368,433 over the last 90 days. 1.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.